Skip to content
    Guidelines & Consensus

    2025 ATA Thyroglobulin Cutoff After Total Thyroidectomy

    Endo et alThe Journal of clinical endocrinology and metabolism

    2025 ATA Thyroglobulin Cutoff After Total Thyroidectomy
    In patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy without radioactive iodine (RAI), the 2025 American Thyroid Association (ATA) guidelines raised the unstimulated thyroglobulin (Tg) cutoff for remission from ≤0.2 ng/mL to 2.5 ng/mL to minimize overtreatment. In a retrospective cohort study evaluating this cutoff across 205 eligible patients (118 ATA low-risk, 42 low-intermediate risk, and 45 intermediate-high risk) followed for a mean of 85 months, increasing the threshold expanded the excellent response classification from 76% to 98%.
    The revised cutoff performed safely in ATA low-risk DTC, where no structural recurrences were overlooked. Conversely, 3.5% of patients with low-intermediate or higher-risk disease developed structural recurrence despite meeting the updated <2.5 ng/mL criteria for an excellent response. In this higher-risk subgroup, recurrences occurred at a median of 22 months, and a lower postoperative Tg cutoff of 0.3 ng/mL was required to achieve 100% sensitivity for structural disease. There were no thyroid cancer-related deaths observed in the study.
    These findings suggest that while the 2025 ATA Tg threshold safely reduces overtreatment in low-risk DTC, its application requires risk-adapted interpretation. For patients harboring low-intermediate or higher recurrence risk, reliance solely on the 2.5 ng/mL threshold may miss early disease, underscoring the ongoing necessity of regular imaging surveillance even after achieving an excellent biochemical response under current guidance.

    Key Takeaways

    • Applying the 2025 ATA unstimulated thyroglobulin threshold of <2.5 ng/mL increased the proportion of patients classified with an excellent response from 76% to 98% without missing any structural recurrences among ATA low-risk patients.
    • Among patients with low-intermediate or higher-risk disease, 3.5% experienced structural recurrence despite meeting the revised excellent response criteria (median time to recurrence: 22 months), whereas a postoperative thyroglobulin threshold of 0.3 ng/mL achieved 100% sensitivity.
    Read the original sourceThe Journal of clinical endocrinology and metabolism